Welcome to our dedicated page for AerSale Corporation news (Ticker: $ASLE), a resource for investors and traders seeking the latest updates and insights on AerSale Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AerSale Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AerSale Corporation's position in the market.
AerSale (Nasdaq: ASLE) reported first-quarter 2024 revenue of $90.5 million, up from $78.3 million in the prior year. GAAP net income was $6.3 million compared to $5 thousand before. Adjusted Net Income1 rose to $5.5 million from $3.3 million, with Adjusted EBITDA1 reaching $9.0 million, up from $5.0 million. Flight equipment sales saw a boost, with inventory reaching $350.1 million. Asset Management Solutions revenue grew to $59.3 million, and TechOps revenue increased to $31.3 million. Gross margin improved to 31.8%, and SG&A expenses decreased to $24.1 million. Non-GAAP Financial Measures were positive, with adjusted EBITDA, adjusted Net Income, and adjusted diluted EPS seeing increases. The Company ended the quarter with $128.9 million in liquidity. The Engineered Solutions segment continues to progress, with the Enhanced Flight Vision System gaining traction. The Company will host a conference call to discuss these results.
